PUBLICATIONS
TALETRECTINIB
Taletrectinib in TKI-Naïve Patients With ROS1+ NSCLC: Updated Data From TRUST-I and TRUST-II
Taletrectinib in TKI-Pretreated Patients With ROS1+ Non-Small Cell Lung Cancer: Updated Data From TRUST-I and TRUST-II
Subgroup Analysis of Japanese Patients in the Phase II Study of Taletrectinib in Patients with ROS1+ NSCLC: The Global TRUST-II Study
Updated Efficacy and Safety of Taletrectinib in Patients With ROS1+ Non-Small Cell Lung Cancer: The Global TRUST-II Study
Taletrectinib, a Next-Generation Selective ROS1 Inhibitor, Exhibits a Differentiated Profile in ROS1 Fusion Models
Taletrectinib, a next-generation selective ROS1 inhibitor, inhibits growth of ROS1 wild-type and ROS1-G2032R xenografts
Taletrectinib vs. Crizotinib in ROS1-Positive Non-Small Cell Lung Cancer: A Matching-Adjusted Indirect Comparison
Efficacy and Safety of Taletrectinib in Chinese Patients with ROS1+ Non-Small Cell Lung Cancer: The Phase II TRUST-I Study
DOI: 10.1200/JCO.24.00731
Efficacy and Safety of Taletrectinib in Patients with ROS1+ NSCLC: Interim Analysis of Global TRUST-II Study
Updated Efficacy and Safety of Taletrectinib in Patients with ROS1+ Non–Small Cell Lung Cancer
TRUST-II: a Global Phase II Study of Taletrectinib in ROS1-Positive Non-Small-Cell Lung Cancer and Other Solid Tumors
PMID: 36877099
Efficacy of Taletrectinib (AB-106/DS-6051b) in ROS1+ NSCLC: An Updated Pooled Analysis of U.S. and Japan Phase 1 Studies
PMID: 34589973 PMCID: PMC8474193
DOI: 10.1016/j.jtocrr.2020.100108
U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors
PMID: 32591465
DOI: 10.1158/1078-0432.CCR-20-1630
The New-Generation Selective ROS1/NTRK Inhibitor DS-6051b Overcomes Crizotinib Resistant ROS1-G2032R Mutation in Preclinical Models
PMID: 31399568 PMCID: PMC6688997
DOI: 10.1038/s41467-019-11496-z
Safety and Pharmacokinetics of DS-6051b in Japanese Patients with Non-small Cell Lung Cancer Harboring ROS1 Fusions: a Phase I Study
PMID: 29805770 PMCID: PMC5955103
DOI: 10.18632/oncotarget.25263
SAFUSIDENIB
The information provided on this website is for informational purposes only. While we strive to keep the content accurate, complete, and up to date, we make no representations or warranties of any kind, express or implied, about the accuracy, reliability, suitability, or availability of any information contained on this website. The content on this website may become outdated over time, and we are under no obligation to update or revise any information. Any reliance on such information is strictly at the user’s own risk. Nuvation Bio shall not be liable for damages of any kind, including without limitation, any special, direct or indirect, incidental, or consequential or punitive damages (even if Nuvation Bio has been advised of the possibility of such damages) arising out of use of the information contained on this website, or any errors or omissions, misprints, out-of-date information, technical, typographical or other errors appearing on this website.
